V2ACT Therapeutics

V2ACT Therapeutics, LLC is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. aimed at developing and testing V2ACT. The fundamental principle of V2ACT comes from compelling scientific evidence, demonstrating that it can achieve superior efficacy safely: vaccination increases the number of neoantigen-specific T cells in the body, and Olvi-Vec can kill cancer cells and enhance the ability of T cells by increasing the receptivity of cancer tissues to adoptively transferred neoantigens.